Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma

NCT03706547 is registered in ClinicalTrials.gov with Peng Liu as lead sponsor.

NCT NCT03706547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Lead sponsor
Peng Liu
Phase
Phase 1
Overall status
Unknown status
Start date
October 30, 2018
Completion date
December 31, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma progression